Clinical trial results:
An Open Label Follow-up Study of Patients Who Participated in Clinical Study B9R-HL-GDDV

Summary

EudraCT number	2007-000469-39
Trial protocol	FI
Global end of trial date	21 September 2007

Results information

Result version number	v1 (current)
This version publication date	23 August 2019
First version publication date	23 August 2019

Trial information

Trial identification

Sponsor protocol code	B9R-HL-GDGN

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	11890: Trial ID

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-285-4559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 September 2007
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	21 September 2007
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to obtain adult height measurement on all 20 subjects with Prader Willi Syndrome (PWS) who participated in the one-year trial (B9R-HL-GDDV) of GH treatment in 1997 – 1999. In patients who have achieved their final height, the result will be compared to the predicted adult heights from the previous study (before starting GH and at one year).

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 May 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Finland: 20
Worldwide total number of subjects	20
EEA total number of subjects	20

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	20
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0

Subject disposition

Recruitment

Recruitment details:

All participants who had received Growth Hormone (GH) therapy in study B9R-HL-GDDV and completed that study were eligible to participate in the B9R-HL-GDGN study.

Pre-assignment

Screening details:

No text entered.

Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	All Participants

Arm description:

All participants who were diagnosed with Prader-Willi syndrome as a child and received recombinant human growth hormone (rhGH) treatment in study B9R-HL-GDDV. B9R-HL-GDGN is a non-drug, non-interventional study.

Arm type	Standard Care
Investigational medicinal product name	Recombinant Human Growth Hormone (rhGH)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

B9R-HL-GDGN was a non-drug interventional study. Recombinant growth hormone therapy was implemented according to normal clinical practice.

Number of subjects in period 1	All Participants
Started	20
Completed	19
Not completed	1
Refused to participate in Follow-up	1

Baseline characteristics

Reporting groups	
Reporting group title	Overall
Reporting group description:	
All participants who agreed to participate in the 10-year follow-up study B9R-HL-GDGN.	

Reporting group values	Overall	Total	
Number of subjects	20	20	
Age categorical			
Units: Subjects			

Age continuous			
Age data here represent the ages of participants while participating in the original study (B9R-HL-GDDV) in 1997-1999. B9R-HL-GDGN was conducted as a follow-up study 10 years later.			
Units: years			
arithmetic mean	6.6		
standard deviation	± 2.5	-	
Gender categorical			
Units: Subjects			
Female	6	6	
Male	14	14	
Height Standard Deviation Score (SDS)			
Height SDS reports the number of standard deviations from the mean for age and sex for an individual measurement (normal range is -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicate greater height.			
Units: Standard Deviations			
arithmetic mean	-0.85		
standard deviation	± 1.2	-	

End points

End points reporting groups

Reporting group title	All Participants
Reporting group description:	
All participants who were diagnosed with Prader-Willi syndrome as a child and received recombinant human growth hormone (rhGH) treatment in study B9R-HL-GDDV. B9R-HL-GDGN is a non-drug, non-interventional study.	
Subject analysis set title	Male participants
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Male participants.	
Subject analysis set title	Female Participants
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Female participants.	

Primary: Mean Adult Height Measurement

End point title	Mean Adult Height Measurement[1]
End point description:	
Mean adult height measurement of participants who achieved their final height.	
Analysis Population Description: All participants who agreed to participate in this 10-year follow-up study and achieved final height.	
End point type	Primary
End point timeframe:	
10 Year Follow-up Visit	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This is a single arm study, there are no comparison groups for statistical analysis.	

End point values	Male participants	Female Participants		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	9	4		
Units: Centimetres				
arithmetic mean (standard deviation)	176.1 (± 4.6)	156.4 (± 8.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Expected Adult Height Standard Deviation Score (SDS) Compared to Achieved Adult Height SDS

End point title	Expected Adult Height Standard Deviation Score (SDS) Compared to Achieved Adult Height SDS
End point description:	
Standard Deviation Score reports the number of standard deviations from the mean for age and sex for	

an individual measurement (normal range: -2 to +2 SDS). Height SDS is derived by subtracting the population mean from individual's height value and then dividing that difference by the population standard deviation. Greater height SDS values indicates greater height.

Analysis Population Description: All participants who agreed to participate in the 10-year follow-up study and achieved adult height.

End point type	Secondary

End point timeframe:

10 Year Follow-up Visit

End point values	All Participants			
Subject group type	Reporting group			
Number of subjects analysed	13			
Units: Standard Deviation Score				
arithmetic mean (standard deviation)				
Expected Adult Height SDS	0.21 (± 0.4)			
Achieved Adult Heights SDS	-0.58 (± 1.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Body Composition (Fat vs. Lean Body Mass [LBM]) Assessed by Dual-energy X-ray Absorptiometry (DEXA)

End point title	Body Composition (Fat vs. Lean Body Mass [LBM]) Assessed by Dual-energy X-ray Absorptiometry (DEXA)

End point description:

Body composition (lean body mass and fat mass) was assessed using dual energy x-ray absorptiometry (DEXA).

Analysis Population Description: All participants who a participated in this 10-year follow-up study.

End point type	Secondary

End point timeframe:

10 Year Follow-up Visit

End point values	All Participants			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: grams				
arithmetic mean (standard deviation)				
Fat Mass Total Body	58558.7 (± 26896.86)			
Lean Mass Total Body	49073.1 (± 13581.46)			

Statistical analyses

No statistical analyses for this end point

Secondary: Health Related Quality of Life (HRQol) 16D

End point title	Health Related Quality of Life (HRQol) 16D

End point description:

The HRQoL 16D is a generic self-assessment measure of health-related dimensions: mobility, vision, hearing, breathing, sleeping, eating, elimination, speech, mental function, discomfort and symptoms, school and hobbies, friends, physical appearance, depression, distress, and vitality. Within each dimension are 5 ordinal levels (1-5) by which that attribute is distinguished. The participant selects the level within in each dimension that best describes his/her current health status. The higher number indicates better health. Calculation of the final score by algorithm has a maximum score of 1.0. The 16D score -representing overall health and quality of life with a range from 0 (worst possible) to 1 (best possible) -is calculated by combining previously determined dimension importance ratings and desirability values with the participants own assessment of each dimension.

Population Analysis Description: All participants who agreed to participate in this 10-year follow-up study.

End point type	Secondary

End point timeframe:

10 Year Follow-up Visit

End point values	All Participants			
Subject group type	Reporting group			
Number of subjects analysed	19			
Units: Unit on a Scale				
arithmetic mean (standard deviation)				
Vitality	.8579 (± .21046)			
Vision	.9149 (± .11448)			
Breathing	.8445 (± .22024)			
Distress	.7886 (± .19677)			
Hearing	.9691 (± .09270)			
Sleeping	.9022 (± .21202)			
Eating	.9799 (± .08764)			
Discomfort and Symptoms	.8299 (± .18416)			
Speech	.7698 (± .24409)			
Appearance	.9345 (± .13026)			

School and Hobbies	.7564 (± .23118)			
Mobility	.9029 (± .16694)			
Friends	.7017 (± .33682)			
Mental Function	.7483 (± .25735)			
Elimination	.8982 (± .20681)			
Depression	.8614 (± .19097)			
Total D16 Score	.8514 (± .10314)			

Statistical analyses

No statistical analyses for this end point

Secondary: Total Weight

End point title	Total Weight

End point description:

Analysis Population Description: All participants who agreed to participate in this 10-year follow-up study.

End point type	Secondary

End point timeframe:

10 Year Follow-up Visit

End point values	Male participants	Female Participants		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	9	5		
Units: kilograms				
arithmetic mean (standard deviation)	114.2 (± 24.9)	96.4 (± 19.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Sleep Polygraphy

End point title	Sleep Polygraphy

End point description:

Sleep polygraphy was performed at the 1- year follow-up visit using a portable monitoring device (PM). Results of the sleep polygraphy were graded as normal, slightly abnormal, and markedly abnormal based on the rate of occurrence of apnea/hypopnea and other findings, including sleep position and reactions to apnea events.

Analysis Population Description:All participants who agreed to participate in this 10-year follow-up study

and had evaluable polygraphy.

End point type	Secondary

End point timeframe:

10 Year Follow-up Visit

End point values	All Participants			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Participants				
Normal	7			
Slightly Abnormal	9			
Markedly Abnormal	2			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]

Timeframe for reporting adverse events:

Entire study.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	10.0

Reporting groups

Reporting group title	Overall

Reporting group description:

All participants who a participated in 10-year follow-up study.

Serious adverse events	Overall		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 20 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Overall		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 20 (0.00%)		

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: There were no adverse events for this trial.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported